特应性皮炎的全身治疗:欢迎加入革命。

Q1 Medicine Seminars in cutaneous medicine and surgery Pub Date : 2017-12-01 DOI:10.12788/j.sder.2017.051

Lawrence F Eichenfield, Linda F Stein Gold

{"title":"特应性皮炎的全身治疗:欢迎加入革命。","authors":"Lawrence F Eichenfield, Linda F Stein Gold","doi":"10.12788/j.sder.2017.051","DOIUrl":null,"url":null,"abstract":"Until recently, systemic therapy of atopic dermatitis was limited to off-label use of immunomodulators, which can pose significant safety concerns, and treatment with systemic corticosteroids, not recommended in the most recent guidelines. The introduction of dupilumab in 2017 marked a major advance in systemic therapy for atopic dermatitis. It has demonstrated long-term efficacy in adults with moderate to severe disease, and is being studied in children. Several other biologic agents and \"small molecules\" with varying mechanisms of action are in phase 2 or 3 development. Semin Cutan Med Surg 36(supp4):S103-S105.","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"36 4S","pages":"S103-S105"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution.\",\"authors\":\"Lawrence F Eichenfield, Linda F Stein Gold\",\"doi\":\"10.12788/j.sder.2017.051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Until recently, systemic therapy of atopic dermatitis was limited to off-label use of immunomodulators, which can pose significant safety concerns, and treatment with systemic corticosteroids, not recommended in the most recent guidelines. The introduction of dupilumab in 2017 marked a major advance in systemic therapy for atopic dermatitis. It has demonstrated long-term efficacy in adults with moderate to severe disease, and is being studied in children. Several other biologic agents and \\\"small molecules\\\" with varying mechanisms of action are in phase 2 or 3 development. Semin Cutan Med Surg 36(supp4):S103-S105.\",\"PeriodicalId\":21714,\"journal\":{\"name\":\"Seminars in cutaneous medicine and surgery\",\"volume\":\"36 4S\",\"pages\":\"S103-S105\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in cutaneous medicine and surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12788/j.sder.2017.051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cutaneous medicine and surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/j.sder.2017.051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

摘要

直到最近，特应性皮炎的全身治疗仅限于免疫调节剂的适应症外使用，这可能会引起重大的安全问题，并且在最近的指南中不建议使用全身皮质类固醇治疗。2017年dupilumab的引入标志着特应性皮炎全身治疗的重大进展。它已证明对患有中度至重度疾病的成人有长期疗效，目前正在对儿童进行研究。其他几种具有不同作用机制的生物制剂和“小分子”正处于第二或第三阶段的开发中。Semin皮肤医学外科杂志36(增刊4):S103-S105。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution.

Until recently, systemic therapy of atopic dermatitis was limited to off-label use of immunomodulators, which can pose significant safety concerns, and treatment with systemic corticosteroids, not recommended in the most recent guidelines. The introduction of dupilumab in 2017 marked a major advance in systemic therapy for atopic dermatitis. It has demonstrated long-term efficacy in adults with moderate to severe disease, and is being studied in children. Several other biologic agents and "small molecules" with varying mechanisms of action are in phase 2 or 3 development. Semin Cutan Med Surg 36(supp4):S103-S105.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in cutaneous medicine and surgery 医学-皮肤病学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Cutaneous Medicine and Surgery (SCMS) presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.